COLUMBUS, Ohio and CHICAGO, June 1, 2026
Paradigm Health has announced the successful implementation of its SPIRE (Scalable Platform for Integrated Research and Evidence) clinical trial solution to support a major multicenter observational oncology study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study, known as DESTINY-PanTumor04, evaluates the real-world effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2 IHC 3+ solid tumors and represents an important advancement in technology-enabled clinical research. Designed as a hybrid observational post-marketing commitment study, the trial leverages Paradigm Health’s AI-powered infrastructure to streamline study design, patient identification, enrollment, data collection, and evidence generation. The initiative demonstrates how digital innovation is reshaping oncology research by making clinical trials more efficient, scalable, and accessible across community practices, academic medical centers, and hospital networks. As healthcare organizations increasingly seek faster and more reliable methods of generating real-world evidence, Paradigm Health’s SPIRE platform is emerging as a powerful solution capable of accelerating clinical development while reducing operational burdens for research sites and sponsors.
SPIRE Platform Modernizes Clinical Trial Operations
The DESTINY-PanTumor04 study is designed to enroll approximately 100 patients across up to 30 sites throughout the United States, ranging from community oncology practices to leading academic institutions. At the core of the initiative is Paradigm Health’s SPIRE infrastructure, which integrates data collection and research workflows directly into routine clinical care. The platform helps automate traditionally labor-intensive processes, including site selection, patient identification, enrollment tracking, and data management. By reducing manual tasks and accelerating access to analysis-ready datasets, SPIRE enables investigators to focus more on patient care and scientific outcomes.
The system’s ability to connect fragmented clinical databases while maintaining data quality and completeness addresses one of the most significant challenges facing modern clinical research. Industry experts believe that technology-enabled infrastructure solutions like SPIRE have the potential to significantly shorten study timelines while enhancing the quality of evidence generated from real-world healthcare settings.
Real-World Evidence Generation Supports Oncology Innovation
Advertisement
One of the defining characteristics of the DESTINY-PanTumor04 study is its pragmatic design, which reflects real-world clinical practice rather than highly controlled experimental environments. The trial incorporates broad eligibility criteria, routine patient care settings, and integrated use of multiple clinical data sources to evaluate treatment effectiveness. This approach allows researchers to generate evidence that more accurately reflects how therapies perform in everyday healthcare environments. Currently, 13 community oncology centers are actively participating in the study, demonstrating the platform’s ability to support research across diverse healthcare settings.
By enabling participation from both academic and community-based institutions, SPIRE helps expand access to research opportunities and improves representation among patient populations. The resulting data may provide valuable insights into treatment outcomes while supporting regulatory, clinical, and commercial decision-making. As oncology research continues to move toward patient-centered and real-world evidence models, pragmatic studies such as DESTINY-PanTumor04 are becoming increasingly important components of modern drug development and post-marketing evaluation strategies.
AI-Powered Infrastructure Aligns with FDA Innovation Initiatives
Paradigm Health’s announcement comes amid growing industry interest in Real-Time Clinical Trials, an emerging concept designed to accelerate clinical trial execution and regulatory review. The same data collection technology powering SPIRE is currently being utilized in a proof-of-concept collaboration with the U.S. Food and Drug Administration (FDA) aimed at evaluating real-time review capabilities for clinical studies. By automating data capture, analysis, and reporting, the platform enables faster identification of key efficacy and safety signals while improving communication between sponsors, investigators, and regulators. The integration of artificial intelligence, electronic health record systems, and advanced analytics has the potential to transform how clinical trials are conducted in the future.
As pharmaceutical companies increasingly seek more efficient methods of generating high-quality evidence, platforms like SPIRE may play a pivotal role in reducing study complexity, lowering operational costs, and accelerating access to innovative therapies. The successful implementation of SPIRE in DESTINY-PanTumor04 highlights the growing convergence of digital health technology, oncology research, and regulatory innovation, creating new opportunities to advance clinical development and improve patient outcomes worldwide.
Source: Paradigm Health press release
